Apellis Pharmaceuticals Inc (NASDAQ: APLS) is -16.59% lower on its value in year-to-date trading and has touched a low of $19.83 and a high of $94.75 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The APLS stock was last observed hovering at around $48.72 in the last trading session, with the day’s gains setting it 1.21%.
Currently trading at $49.93, the stock is -7.25% and -15.49% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing 2.48% at the moment leaves the stock -3.99% off its SMA200. APLS registered -43.75% loss for a year compared to 6-month gain of 9.98%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -10.08% loss in the last 1 month and extending the period to 3 months gives it a -24.94%, and is 3.96% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.11% over the week and 5.01% over the month.
Apellis Pharmaceuticals Inc (APLS) has around 706 employees, a market worth around $6.02B and $396.59M in sales. Fwd P/E is 34.69. Profit margin for the company is -133.29%. Distance from 52-week low is 151.79% and -47.30% from its 52-week high. The company has generated returns on investments over the last 12 months (-176.79%).
The EPS is expected to grow by 79.74% this year
The shares outstanding are 119.56M, and float is at 98.84M with Short Float at 10.56%.
Apellis Pharmaceuticals Inc (APLS) Insider Activity
The most recent transaction is an insider sale by Deschatelets Pascal, the company’s Chief Scientific Officer. SEC filings show that Deschatelets Pascal sold 69,107 shares of the company’s common stock on Apr 08 ’24 at a price of $54.17 per share for a total of $3.74 million. Following the sale, the insider now owns 1.12 million shares.
Apellis Pharmaceuticals Inc disclosed in a document filed with the SEC on Apr 01 ’24 that Sullivan Timothy Eugene (Chief Financial Officer) sold a total of 4,000 shares of the company’s common stock. The trade occurred on Apr 01 ’24 and was made at $58.66 per share for $0.23 million. Following the transaction, the insider now directly holds 93338.0 shares of the APLS stock.
Still, SEC filings show that on Mar 19 ’24, Dunlop A. Sinclair (Director) disposed off 18,681 shares at an average price of $57.18 for $1.07 million. The insider now directly holds 173,998 shares of Apellis Pharmaceuticals Inc (APLS).
